High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 60, Issue 12, 2013, Pages 2042-2046

  Altaf, Sadaf ^a   Enders, Felicity ^a   Jeavons, Elysia ^a   Krailo, Mark ^b   Barkauskas, Donald A ^b   Meyers, Paul ^c   Arndt, Carola ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Obesity; Osteosarcoma; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; MURAMYL TRIPEPTIDE;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHILD; CHILD NUTRITION; CREATININE CLEARANCE; EVENT FREE SURVIVAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NEPHROTOXICITY; NUTRITIONAL STATUS; OBESITY; OSTEOSARCOMA; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE TRANSFUSION; UNDERWEIGHT;

CHEMOTHERAPY; OBESITY; OSTEOSARCOMA; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; OBESITY; ORTHOPEDIC PROCEDURES; OSTEOSARCOMA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84885738766     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24580     Document Type: Article

References (21)

1. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007; 25:2063-2069.
2. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005; 293:203-211.
3. Inaba H, Surprise HC, Pounds S, et al. Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer 2012; 118:5989-5996.
4. Flegal KM. Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav 2005; 86:599-602.
5. Ogden CL, Flegal KM. Changes in terminology for childhood overweight and obesity. Natl Health Stat Report 2010; 1-5.
6. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from Intergroup Trial 0114. J Clin Oncol 2004; 22:648-657.
7. Dickson TM, Kusnierz-Glaz CR, Blume KG, et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 1999; 5:299-305.
8. Fleming DR, Rayens MK, Garrison J. Impact of obesity on allogeneic stem cell transplant patients: A matched case-controlled study. Am J Med 1997; 102:265-268.
9. Nardin A, Lefebvre ML, Labroquere K, et al. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 2006; 6:123-133.
10. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23:2004-2011.
11. Rogers PC, Melnick SJ, Ladas EJ, et al. Children's oncology group (COG) nutrition committee. Pediatr Blood Cancer 2008; 50:447-450; discussion 451.
12. Bielack SS, Carrle D, Hardes J, et al. Bone tumors in adolescents and young adults. Curr Treat Options Oncol 2008; 9:67-80.
13. Hingorani P, Seidel K, Krailo M, et al. Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: A report from the Children's Oncology group. Pediatr Blood Cancer 2011; 57:939-942.
14. Ghobadi C, Johnson TN, Aarabi M, et al. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: Expected variations in clearance. Clin Pharmacokinet 2011; 50:809-822.
15. Thomas DM, Herschtal A, Hay B, et al. A pooled analysis of factors affecting outcomes in 2407 patients from 16 adjuvant clinical trials in osteosarcoma. CTOS 16th Annual Meeting: Paris, France; 2010. p 38.
16. Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: An analysis from the German Hodgkin study group. J Clin Oncol 2005; 23:8003-8011.
17. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553-1561.
18. Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012; 51:277-304.
19. Langebrake C, Bernhardt F, Baehr M, et al. Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation. Int J Clin Pharm 2011; 33:918-924.
20. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17:4-12.
21. Warner JT, Cowan FJ, Dunstan FD, et al. The validity of body mass index for the assessment of adiposity in children with disease states. Ann Hum Biol 1997; 24:209-215.